摘要
OBJECTIVES This study explored and analyzed the application value of oXiris- endotoxin adsorption technology in patients with sepsis. METHODS 23 sepsis patients hospitalized from January 2018 to September 2019 in our ICU center and received oxiris-endotoxin adsorption were enrolled as the observation group, and another 30 sepsis patients hospitalized during the same period were selected as the control group who treated with routine continuous renal replacement therapy (CRRT). The heart rate, respiratory rate, norepinephrine (NE) dosage, lactic acid, procalcitonin (PCT), urine volume, and sofa scores that evaluate organ failure after systemic infection, as well as ICU stay, organ support duration, and incidence of cardiovascular events were compared between the two groups before and after treatment. RESULTS The heart rate, respiratory rate and NE dosage of the two groups post-treatment were dramatically lower than those pre-treatment (P<0.05), and these indexes in observation group after treatment were critically lower than those in control group (P<0.05). The lactic acid, PCT, urine volume and sofa scores of the two groups were dramatically lower than those before treatment (P<0.05), and the indexes in observation group after treatment were notably lower than those in control group (P<0.05). The degree of serum IL-6, IL-10 and endotoxin in two groups after operation decreased remarkably than that before treatment (P<0.05), and the observation group had obviously lower indicator degree than the control group (P<0.05). The ICU stay, organ support duration, and incidence of cardiovascular events in the observation group were notably lower than those in the control group (P<0.05). CONCLUSION compared with the traditional CRRT technology, the oXiris membrane based CRRT technology can effectively improve the hemodynamic indicators of patients with sepsis, reduce the level of inflammation, and improve the metabolic function of body, thereby improving the patients' organ function. It has good clinical application value in patients with sepsis.